UW Carbone Experts Lead Sessions at World's Largest Cancer Meeting
Pictured above (l-r): UW Carbone Cancer Center faculty leading discussions at ASCO include Dr. Kari Wisinski, Dr. Dustin Deming, Dr. Mark Burkard, Dr. Ruth O'Regan and Dr. Noelle LoConte. Not pictured above: Dr. Lee Wilke and Dr. Doug McNeel.
Chicago, IL. - From the best treatment for early-stage breast cancer to the role of alcohol in causing cancer, University of Wisconsin Carbone Cancer Center faculty led discussions of the latest cancer research at the world’s largest gathering of cancer specialists.
The American Society of Clinical Oncology (ASCO)’s annual meeting was held at McCormick Place on Chicago’s Lake Michigan waterfront. The event drew about 40,000 oncologists and related professionals from around the world.
Dr. Lee Wilke, a breast cancer surgeon who leads the UW Health Breast Center, led a Clinical Problems in Oncology session on evidence-based decision-making for patients with local or regional breast cancer. Wilke’s session, titled “When Less is More,” looked at making the best surgical and therapeutic decisions for patients with ductal cancer in situ. She also talked about how to determine the ideal length for radiation therapy following breast cancer surgery, highlighting a trend towards shorter treatment times.
Dr. Mark Burkard, a breast cancer specialist who co-leads Wisconsin’s Precision Medicine Molecular Tumor Board, led a session titled, “How Does The Practicing Oncologist Make Sense of a Genomic Report?”
Burkard talked about the many genetic mutations that show up in pathology reports and how to zero in on the ones most likely to drive the cancer.
Carbone breast cancer oncologists took part in a session on metastatic breast cancer. Dr. Kari Wisinski reviewed the results of new clinical trials and looked at how oncologists can incorporate these results into everyday practice. And later in that session, Dr. Ruth O’Regan, who directs the division of medical oncology/hematology at Carbone, talked about evolving approaches in treating triple-negative breast cancer.
Carbone oncologists also chaired two of the day’s larger sessions. In the enormous D2 lecture hall, O’Regan chaired the afternoon session on metastatic breast cancer.
At the same time, Dr. Noelle LoConte, a specialist in GI cancers and cancer prevention, co-led the morning session on Cancer Prevention, Hereditary Genetics and Epidemiology. As part of that session, Burkard again explored the world of precision medicine, with a presentation called “Patient Evaluation in an Expanding Genetic World: Multiple Genes, Multiple Cancers, Multiple Molecular Signatures.”
Dr. Dustin Deming, a specialist in colorectal cancer and co-leader of Carbone’s Precision Medicine Molecular Tumor Board, looked at new research on biomarkers for anorectal cancer.
LoConte also chaired another session, Lifestyle Modifications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety and Alcohol Reduction. LoConte authored the recent ASCO position paper on alcohol as a cause of cancer and will discuss that research during the session, as well. LoConte is the principal investigator of the Wisconsin Comprehensive Cancer Control Program, which seeks to reduce cancer rates in Wisconsin.
Dr. Douglas McNeel, a prostate cancer expert and Carbone’s director of solid tumor immunology research, led a discussion of oral abstracts in a talk titled “On the Frontier: Immunotherapy and Radiopharmaceutical Therapy in Prostate Cancer.” McNeel has led efforts over 20 years in developing immune-based treatments for prostate cancer.
O’Regan kicked off the conference’s final day with an early morning session that focused on Highlights of the Day in breast cancer treatment.
In addition to the oral presentations, Carbone researchers, scientists and students presented early research during poster sessions throughout the conference.
Date Published: 05/31/2018